# Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients

> **NCT04762628** · NA · COMPLETED · sponsor: **Saisei Pharma** · enrollment: 600 (actual)

## Conditions studied

- Covid19

## Interventions

- **DIETARY_SUPPLEMENT:** MAF capsules 148 mg
- **DIETARY_SUPPLEMENT:** M capsules 148 mg
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04762628
- **Lead sponsor:** Saisei Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-27
- **Primary completion:** 2021-07-05
- **Final completion:** 2021-08-06
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762628, "Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04762628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*